​

BioLineRx (BLRX) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

BLRX Stock Rating

BioLineRx stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

BLRX Price Target Upside V Benchmarks

TypeNameUpside
StockBioLineRx-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$5.29$5.29$5.29
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2511---2
May, 251-1--2
Apr, 25111--3
Mar, 2511---2
Feb, 2511---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 15, 2023NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.94-----
Avg Forecast$-0.98$-0.05$-0.08$-0.04$-0.02$0.02
High Forecast$-0.36$-0.03$-0.08$-0.01$-0.01$0.03
Low Forecast$-1.67$-0.07$-0.09$-0.06$-0.03$0.01
Surprise %-4.08%-----

Revenue Forecast

$0 $6M $12M $18M $24M $30M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.80M-----
Avg Forecast$150.00K$24.91M$4.29M$7.27M$9.84M$13.70M
High Forecast$158.82K$25.60M$6.45M$11.21M$15.16M$21.11M
Low Forecast$132.35K$24.21M$2.14M$3.72M$5.04M$7.01M
Surprise %3100.00%-----

Net Income Forecast

$-2B $-2B $-1B $-500M $0 $500M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-60.61M-----
Avg Forecast$-944.10M$-47.96M$-80.28M$-33.72M$-19.27M$19.27M
High Forecast$-344.88M$-26.98M$-74.55M$-12.32M$-7.04M$32.82M
Low Forecast$-1.61B$-68.93M$-86.01M$-57.44M$-32.82M$7.04M
Surprise %-93.58%-----

BLRX Forecast FAQ

Is BioLineRx stock a buy?

BioLineRx stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioLineRx is a favorable investment for most analysts.

What is BioLineRx's price target?

BioLineRx's price target, set by 7 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $5.29.

How does BioLineRx stock forecast compare to its benchmarks?

BioLineRx's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for BioLineRx over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 0% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is BioLineRx’s EPS forecast?

BioLineRx's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.05, marking a -94.68% decrease from the reported $-0.94 in 2023. Estimates for the following years are $-0.08 in 2025, $-0.04 in 2026, $-0.02 in 2027, and $0.02 in 2028.

What is BioLineRx’s revenue forecast?

BioLineRx's average annual revenue forecast for its fiscal year ending in December 2024 is $24.91M, reflecting a 419.01% increase from the reported $4.8M in 2023. The forecast for 2025 is $4.29M, followed by $7.27M for 2026, $9.84M for 2027, and $13.7M for 2028.

What is BioLineRx’s net income forecast?

BioLineRx's net income forecast for the fiscal year ending in December 2024 stands at $-47.957M, representing a -20.88% decrease from the reported $-60.614M in 2023. Projections indicate $-80.28M in 2025, $-33.718M in 2026, $-19.267M in 2027, and $19.27M in 2028.